key: cord-0743460-opdxzbhz
authors: Murti, Bayu Tri; Putri, Athika Darumas; Huang, Yi-June; Wei, Shih-Min; Peng, Chih-Wei; Yang, Po-Kang
title: Clinically oriented Alzheimer's biosensors: expanding the horizons towards point-of-care diagnostics and beyond
date: 2021-06-08
journal: RSC Adv
DOI: 10.1039/d1ra01553b
sha: 31fb460d35a0def4ddd323e1731d80c0f2df997a
doc_id: 743460
cord_uid: opdxzbhz

The development of minimally invasive and easy-to-use sensor devices is of current interest for ultrasensitive detection and signal recognition of Alzheimer's disease (AD) biomarkers. Over the years, tremendous effort has been made on diagnostic platforms specifically targeting neurological markers for AD in order to replace the conventional, laborious, and invasive sampling-based approaches. However, the sophistication of analytical outcomes, marker inaccessibility, and material validity strongly limit the current strategies towards effectively predicting AD. Recently, with the promising progress in biosensor technology, the realization of a clinically applicable sensing platform has become a potential option to enable early diagnosis of AD and other neurodegenerative diseases. In this review, various types of biosensors, which include electrochemical, fluorescent, plasmonic, photoelectrochemical, and field-effect transistor (FET)-based sensor configurations, with better clinical applicability and analytical performance towards AD are highlighted. Moreover, the feasibility of these sensors to achieve point-of-care (POC) diagnosis is also discussed. Furthermore, by grafting nanoscale materials into biosensor architecture, the remarkable enhancement in durability, functionality, and analytical outcome of sensor devices is presented. Finally, future perspectives on further translational and commercialization pathways of clinically driven biosensor devices for AD are discussed and summarized.

Athika Darumas Putri received her bachelor's in pharmacy from Faculty of Pharmacy, University of Jember, Indonesia. Aerwards, she completed her master's degree from Durban University of Technology, South Africa focusing on cancer aptasensor and computational modelling. She is currently a PhD student in the School of Pharmacy, Taipei Medical University, Taiwan. She specializes in the bio-nano interactions for the effective drug delivery systems and in silico studies.

The prevalence of Alzheimer's disease (AD), 60-70% of dementia's total occurrence, has been increasing extensively worldwide. In 2016, 43.8 million people suffered from dementia, and these statistical gures are expected to even reach 100 million by 2030-2050. 1,2 AD corresponds to an extremely harmful and irreversible neurodegenerative disorder which can gradually cause serious brain problems. 3 Currently, the common approach to characterize AD is by various pathological markers, which include amyloid-b (Ab) plaques, tau proteins, vascular damage, loss of synapses, damaged neuronal cells, formation of dystrophic neurites, noticeable gliosis, etc. [4] [5] [6] To overcome AD, there are two major strategies being actively applied. The rst strategy is to develop new biological and chemical entities for therapeutic usages. For instance, a great deal of effort has been reported to develop chemotherapeutic drugs and their delivery vehicles to effectively eliminate or target the disease biomarkers. However, serious limitations have been found from AD pathophysiology, lacking consensus on crystal-clear comprehension, and heterogeneity of responsible hallmarks. 7, 8 More importantly, this strategy also restricts the development of highly selective medicines to clinically eradicate the biomarkers. In contrast, the second strategy is to establish biomarkers for early-stage detection and progression monitoring via engineered nanomedical approaches. Biosensor is a typical example, leading to the early prevention of the disease and avoid a more severe stage. This strategy has been widely accepted as an appropriate toolbox to overcome AD, which is coherent with the rapid observation on drug discovery and development.

Recently, biosensor technology has been largely explored in the various elds of neurodegenerative diseases. 9,10 Biosensors, as rst terminology coined by Clark and Lyons in 1962, 11 is described by International Union of Pure and Applied Chemistry (IUPAC) as "a device that uses specic biochemical reactions mediated by isolated enzymes, immunosystems, tissues, constructed devices were applied to either blood or human cerebrospinal uid (CSF) samples, while several reports employed minimally invasive samples, such as nasal secretions, saliva, etc. [24] [25] [26] The mainstream development is now directed towards POC device in which testable at the time and place of patient care, capable as a self-testing, as well as complying the ASSURED guideline: Affordable, Sensitive, Specic, Userfriendly, Rapid and Robust, Equipment-free, and Delivered. 27, 28 In this review, we attempt to summarize forward-looking developments of promising detection strategies towards AD, especially for clinically driven biosensors design. The most recent development of biomarkers for AD, biosensor design and state-of-the-art biosensing strategies (i.e., in vitro and in vivo) are presented. Moreover, the importance of in silico study to support the experimental ndings is also briey discussed ( Fig. 1(A) ). Finally, a perspective on the regulation of the biosensor development and commercialization pathways is also provided as future remarks. This aims to signify the emerging role of biosensor in current diagnosis for AD and to address their advancements towards future clinical applications.

Currently, the decisive cause of AD remains unknown. Many hypotheses have been associated with the Alzheimer's etiology including amyloid cascade hypothesis, tau propagation hypothesis, neurotransmitter hypothesis, calcium homeostasis hypothesis, mitochondrial cascade, neurovascular hypothesis, metal ion hypothesis, inammatory hypothesis, exercise hypothesis, virus hypothesis, diabetes hypothesis, lymphatic system hypothesis, etc. 3 Among them, regardless of its recent failure in clinical trials, amyloid hypothesis has been regarded as the mainstream concept underlying AD research in the past two decades. 29 The solid consensus in this eld will be benecial in escalating the successful therapeutic interventions as well as in AD diagnosis.

In the scope of Alzheimer's diagnosis, there were notable reports on biosensor encompassing early detection and disease monitoring. Several biomarkers have recently been utilized such as amyloid, tau, apolipoprotein E4 (ApoE4) gene, a-synuclein, a-1 antitrypsin, acetylcholine, etc. The overview of these biomarkers is illustrated in Fig. 2 . Motivated by the clinical need for biosensor-based diagnosis, the surveyed biosensors are divided into two main categories, i.e., in vitro and in vivo biosensing systems. As for the in vitro, the biosensor device could be applied to test the samples in which the biochemical reactions occur outside of living body. The samples include human based-biouids or articial samples, cell culture, tissue excluding the living organism, and physiologically relevant preclinical analytes. 30, 31 As for the in vivo methodologies, the biosensor device is simply operated inside the body or may be implanted into a living system. 32 Further, an insight into the biosensor architecture potentially used as POC diagnosis of AD is also briey presented.

Biomarkers basically belong to proteins, enzymes, biological metals, genes, small biomolecules, and metabolites which have been largely employed as the bioanalyte in AD biosensor development (Fig. 2) . 33 Ab, tau protein, and phosphorylated tau are shown to be predominant markers for the AD. 33, 34 Additionally, most of them are known to be accumulated in CSF and neuroimaging samples. 35 To date, scientists and clinicians have been working on developing advance tools of AD diagnosis by targeting the various type of biomarkers. 36, 37 For example, the progress on biosensors based on specic Ab detection, 10 and aptamer-based biosensors for AD have been reported. 38 However, it should be noted that a clinically oriented biomarker with appropriate biosensor design for AD has not yet been properly addressed. In the following, we will stress our focus to provide recent developments on biosensors for AD based on biomarker sources employed in pre-clinical and clinical settings.

(a) Ab peptide. Traditionally, AD is marked by the coexistence of Ab plaque depositions as it has been widely accepted as the most hypothetical marker during initiation and progression stage. 39, 40 Ab is a peptide comprising of approximately 40 amino acids on the basis of sequential cleavages of Ab precursor protein (APP). 29 The origin of neurotoxicity in Ab (40) peptides relies on the Ab (residues [16] [17] [18] [19] [20] [21] which is the central hydrophobic segment for the amyloid brillization known as the "amyloidogenic domain". 41-43 CSF contains different types of Ab plaques, where the major compounds correspond to Ab (40) and Ab (42) isoforms. Other forms of peptides are also generated from APP in minor percentages. 44, 45 Interestingly, accumulated amyloid can also be found in several minimally invasive bio-uids including blood, 46 nasal secretion, 24,26 salivary gland biopsy, 47 and retina. 48 These recent studies have turned over the usage of conventional CSF-based biosensors due to less invasive sampling procedure, well-tted with basic principle of POC diagnosis. However, it is noteworthy to mention that their amyloid loads may extensively differ from that of CSF as the gold standard of today's AD clinical diagnosis. For instance, Ab concentrations are 10-fold higher in CSF than in blood plasma. 49 This challenge could be overcome through a proper design of biosensing devices such as truthful biorecognition elements, transducing techniques, and the use of microuidic channel, as well as nanomaterials in supporting the sensor architecture ( Fig. 1(B) ).

In clinical setting, many diagnostic methods have been applied to detect Ab. Traditionally, neuroimaging (e.g., positron emission tomography, magnetic resonance imaging, and near infrared uorescence) is the foremost clinical assessment tool for Ab deposition in vivo. Its imaging quality depends on several factors such as the instrument resolution, the ability of contrast agent to surpass blood-brain barrier (BBB), its specicity towards Ab diffuse, core, and intermediate plaques species. [50] [51] [52] In general, the use of neurological imaging has been limited within community owing to the high analytical cost and operational, and a poor understanding of amyloid burden relationship with cognitive dysfunction. 51,53-56 Instead, immunoassay method (i.e., enzyme-linked immunosorbent assay (ELISA)) has been a plausible choice for the clinical diagnosis of Ab. ELISA is the gold standard immunoassay for CSF Ab (42) detection and is the most frequently used diagnostic method in AD. 36, 52, 57, 58 Tremendous studies have reported the ELISA application in detecting Ab levels in CSF, human plasma, and serum samples. [59] [60] [61] [62] [63] [64] Numerous lab-based ELISA kits have now been available in the market with the detection range of 10 to 1000 pg mL À1 and procient of discriminating AD patients with healthy control with good sensitivity (80%) and moderate specicity (83.3%). 52, 65 In spite of time-consuming and laborious issues of traditional ELISA, the alternative ELISA kits have been widely developed for amyloid detection, which include paper-based ELISA 63 and digital ELISA. 66, 67 Both of them are cost-effective, easy to operate, and portable and thus suitable for POC diagnostic approach. 52, 65 In addition to amyloid-based diagnosis, biomarker for AD is not only relied on Ab molecules (i.e., monomer), but also on their elongated forms 68 so-called Ab oligomers (AbO) and brils. AbO has been regarded as the most neurotoxic entities and meticulously associated with the AD severity than that of insoluble Ab aggregates, 69 specically in the early phase of disease initiation. Their concentrations were observed to be up to 70-fold higher in AD as compared to non-demented controls. 70, 71 The relationship between the Ab assemblies and their toxicity was previously elucidated based upon the peptides binding with the uorescent probes. [72] [73] [74] Due to the higher toxicity of AbO over amyloid brils, the detection of oligomeric amyloid is advantageous to precisely represent the progression of AD, particularly for its early stage. 75, 76 Recently, an electrochemical biosensor design was reported to detect AbO in an in vitro environment using thiolated cellular prion protein peptide as bioreceptor. 71 Antibody is favourable entity to detect amyloid biomarkers owing to its high affinity to the designated antigen. 38, 77 Recently, scientist employed another recognition element such as aptamer to selectively detect AD biomarkers. 38, 78 Aptamer has offered many advantages to biosensor design, such as higher affinity (as compared to classical antibody), less expensive, nonin vivo production, reproducible system, smaller molecular size, and availability for wide range of analytes. 38 In general, aptamer is dened as short sequence of nucleotides (DNA or RNA) that primarily designed to mimic antibody function. Aptamers are three-dimensional bioreceptors with molecular size signicantly smaller than conventional protein antibody. 38 This bioentity is produced by systematic evolution of ligands by exponential enrichment (SELEX) resulting in prominent-affinity and selectivity entities towards analytes. Meanwhile, aptamer is also a fascinating choice in clinically oriented biosensors due to their specicity, biocompatibility, non-toxicity, as well as nonimmunogenic features. 38 As for the current biosensors of AD, aptamers are tenaciously used as an alternative of antibody setting especially for bioreceptor in detection strategy. For instance, aptamer is useful to overcome the Debye-Hückel screening effect in eld-effect transistor (FET)-based biosensor (vide infra), which commonly hinder the electrical signal from the target molecules under high concentrations of such ions. 79 FET, integrated with proper biorecognition elements such as aptamer or antibody, is a unique and useful sensing device to detect biomolecular targets 80-82 offering many advantages such as real-time, highly sensitive, specic, and label-free transduction of biochemical signals. 83, 84 In principle, the sensing mechanism of an FET device involves structural and functional integration of biorecognition element in which the selective interaction of bioreceptors and analyte produces changes in biophysical and biochemical signal. The signal is then transduced and amplied via a eld-effect towards the signal display. 83, 85, 86 Aptamer is highly benecial in this typical device since the biosensing is carried out under the physiological uids 87 such as human CSF and blood. However, aptamer also possesses several limitations while embedded in biosensors, which include lack of high-quality aptamers for clinically important targets and non-specic binding of aptamersurrounding environment. 88 To overcome these limitations, an appropriate biosensor design with functional biomarker is needed, such as the compliment of nanomaterial, sandwichtype aptasensor, antibody complex, and polymer inclusion. 89 Additionally, a major concern has been given upon the failure of amyloid in latest clinical trials in which scientist started to reconsider that predominant role of amyloid in AD pathogenesis. 90, 91 (b) Tau. Tau has been dened as state-of-the-art biomarkers for AD, instead of amyloid peptides. Tau is a microtubule-binding axonal protein that is highly expressed in cortical neurons. 92 While amyloid and tau protein are continuously acknowledged as the predominant markers in AD, the associative mechanism between both remains varied. 93, 94 Recent biomarker studies indicate that Ab accumulation is followed by synaptic dysfunction and increased phosphorylation and secretion of tau. 92, 95 Indeed, Ab propagates the tau pathology into the cortex through direct neuronal connections [96] [97] [98] (Fig. 3) . Human AD cases with plaques and tangles demonstrate a noticeably increased formation and propagation of bioactive, high molecular weight forms of pathological tau relative to primary age tauopathy cases with tangles. 93, 99 Specically, tau is one of the useful biomarkers that is responsible for the formation of neurobrillary tangles. 100, 101 Lisi et al. have developed a SPR-based biosensor platform to detect human tau in the in vitro environment (i.e., articial CSF). 102 The key advantage of targeting tau for sensor technology is its low detection limit within clinical concentration range (pM, picomolar). Herein, instead of using Au NPs for SPR resonance, one dimensional multi-walled-carbon nanotube (1D-MWCNT) materials conjugated with tau antibody were selected to attain a sandwich-based bioassay. The as-fabricated assay is able to enhance the SPR signal of two order ($10 2 ) folds compared to conventional unconjugated sandwich. 102 The platform enables the as-designed sensor system to detect the tau analyte down to 125 pM of limit of detection (LOD) with the 125-1000 pM linear working range. Additionally, they extended similar study by further employing a non-SELEX-based aptamer to sense multitau biomarkers on a chip by using uorescent anisotropy. 103 This remarkable platform can detect t-441, t-381, t-352, and t-383 isoforms with the LOD of 28 nM, 3.2 nM, 6.3 nM and 22 nM, respectively.

A versatile biosensing device, such as a commercial glucometer or alcohol meter, merely initiated with the assay at a nonnatural sample and animal biouids. In other words, the biochemical reaction, as a result of analyte and biorecognition element interaction, occurs outside of a living organism under the in vitro environment, such as a culture dish, a test tube, a microtiter plate, etc. 104 Nowadays, signicant advances from nanotechnology and microfabrication process have shed light on the development of in vitro biosensors. Take microuidic device as an example, the devices fundamentally combine features of computing chip with living cells and tissues mimicking the human biology. 105 Additionally, organon-chips device have also been well-established simply to impersonate the more complex organ systems, since the excellent capability of the biosensors and microuidic system. 106, 107 These advances make the in vitro environment to be one of the plausible choices for biosensor development.

In vitro biosensor, as part of in vitro diagnosis (IVDs), refers to the assays or tests that are carried out on samples such as blood or tissue withdrawn from the human body. By regulation, the IVDs is dened by U.S. FDA as the specic subcategory of medical devices comprising "those reagents, instruments and systems intended for the diagnosis of disease or other conditions". Relevant diagnostics are then suitable with this category, which include a determination of the state of health, cure, mitigation, treatment, and prevention. 108 Moreover, IVDs may also be used in precision and personalized medicine to identify the patients benetting from a particular therapies and treatment. 108, 109 In 2016, the global diagnostics market was counted as US$40-45 billion with POC diagnostics supplying US$12-13 billion. The annual growth rate of IVDs is forecasted to be 5%. 110, 111 The rapidly growing market of IVDs emphasize the prominence of this technology, not only for academia-based research but also in industry. Recently, the global pandemic of COVID-19 also fuels the research and development in pursuit of IVDs technology, especially for cardiovascular diseases, neurological diseases, liver dysfunction, pneumonia, etc.

For the sensing techniques driven to in vitro analysis, several efforts have been conducted for biosensor design targeting AD. 112 For example, a state-of-the-art so material fabricated with DNA origami has been introduced as articial peptide nano-network biosensor to tackle the pathological peptides aggregates in neurodegenerative disease, by imitating pathogenesis process. 31 Particularly, periphery platelet enables itself to secrete amyloid proteins and initiate their cross-linking to establish a surface peptide molecular-based system. This platform could sophistically discriminate the AD patients from healthy volunteers by detecting potential neurodegenerative activity of platelet with the <1 pg mL À1 detection limit and 3.3-3300 pg mL À1 dynamic range, which is superior to ELISA method. This biosensor is potentially used towards the labelfree and early screening (IVDs) of AD biomarkers circulating in minimally invasive blood sample. Table 1 and Fig. 4(A) show the distribution status of state-of-the-art biosensors for AD, the cutting-edge usage of biosensors in anchoring from forefront analyte recognition towards signal amplication and data acquisition. 113 To effectively diagnose AD, various techniques have also been developed towards specic biomarker and sensing strategies, such as uorescent biosensors, immunosensors, electrochemical biosensors, eld-effect transistor-type biosensors etc. (Table 1 and Fig. 4(A) ). 114 Among them, it is noted that electrochemical biosensor has attracted prodigious attentions (i.e., 43.18% in Fig. 4(A) ). More interestingly, in vitro platform occupies the major portion of biosensor development for AD, counting over 95% (Fig. 4(B) ). 114 The reason could be due to the intricate procedure of in vivo biosensor which commonly need to be implanted into the living animal model. Meanwhile, in vivo biosensors also need to concern with the biocompatibility, systemic toxicity, biodegradability of the materials used, that make in vivo biosensors more complex to achieve in comparison with in vitro ones. [115] [116] [117] (a) Electrochemical biosensors. Electrochemical biosensor has been widely applied to biomarker detection due to its capability of achieving extremely low detection limit down to attomolar regimes. 118-127 An electrochemical biosensor is a selfcontained integrated device, which provides quantitative or semi-quantitative analytical data on the basis of interaction between bioreceptor retained in direct spatial contact with an electrochemical transduction element, with the target analyte(s). 13 This platform transduces the biochemical events into electrical signals that is further translated into a readable display. [128] [129] [130] Since the rst electrochemical sensor introduced by Clark and Lyons to measure the blood glucose, 11 the diverse forms of biosensor have been established in various applications. 130 Several types of working modes have been well-established in electrochemical sensors via amperometry, 131 voltammetry, 132 impedimetric, 133 conductometry, 13 and interdigitated microelectrode techniques. 24 The advantages of this sensing platform mainly rely on two aspects i.e., capability of device miniaturization and cost-effective instrumentation. 134 More importantly, some commercialized biosensors have become popular owing to these merits (i.e., POC glucose sensors and alcohol monitoring device). 134, 135 Meanwhile, it is also noted that electrochemical biosensors have been utilized for routine analysis paving the way for POC diagnostics of AD. 10, 22, 23 As for the diagnosis of AD, an electrochemical biosensor platform was recently reported to detect AbO in an in vitro environment using thiolated cellular prion protein peptide as bioreceptor. 71 Moreover, Sun et al. also employed composite hetero-structured nanomaterials and three-dimensional (3D) hydrogel to achieve 0.1 pM detection limit in 0.1-10 nM linear working range, complying the clinical diagnostic concentration of amyloids in human plasma and CSF (5.5-195 pM) . This 3Dhydrogel biosensor composed of graphene oxide (GO)/Au nanoparticles (Au NPs) provided signicantly larger surface area as compared to solid electrode allowing rapid penetration of target biomolecules towards bioreceptor binding moiety. The purpose of utilizing GO in hydrogel is to contribute towards the tunable conductivity and bionic structure of the electrode. Additionally, a differential pulse voltammetry (DPV)-based electrochemical biosensor was employed by Negahdary and Heli to detect Ab (42) in an articial CSF and spiked serum samples. 136 This strategy embedded Ab (42)-binding peptides on the microporous Au nanostructure, and successfully achieved attomolar (aM) level of detection limit i.e., 0.2 pg mL À1 (44.3 aM), with a linear working range of 3-7000 pg mL À1 . Authors further extended the similar work with the use of different biorecognition element i.e., 107-mer thiol-modied RNA aptamer. 129 However, this study represented the slightly higher LOD (i.e., 0.4 pg mL À1 or 88.6 aM) than that of antibody setting.

The results indicate the better compatibility of antibody with the electrochemical-based strategy, in particular for amyloid detection, as compared to aptamer. Indeed, owing to the high surface area during immobilization process, the addition of Au nanomaterials in those studies are another key medium towards the ultrasensitive biosensors device. 129 Another electrochemical biosensing platform was designed to detect Ab in its oligomer by using brain samples of normal mice and with AD. 137 The label-and antibody-free biosensors were fabricated for the AbO detection employing cellular prion protein as a receptor for AbO yielding detection limit at picomolar level (10 À4 pM). In contrast to the classical ELISA method, this platform used PrP C receptor to capture the amyloid target as opposed of antibody suffered from time-consuming procedure and lengthy incubation. Additionally, an electrochemical strategy was developed to measure AbO in vitro acquiring a few mM LOD by dual transducing techniques, where CV and UV-Vis spectrophotometry in human blood serum and articial CSF. 138 This approach utilized the competitive nature of Zn ions and AbO releasing ferrocene from its Zn zeolitic imidazole framework which then subsequently detected by the transducers. This study protocol provided a decent feasibility of using articial sample comprising biomarker of AD.

Actually, instead of amyloid-based marker, melatonin could also be detected by electrochemical method with the prime marker source from rat's liver extracts (spiked with melatonin). 132 Melatonin abnormal circulation have been correlated to several diseases such as AD, type II diabetes mellitus, and several types of cancers. 132, 139 This melatonin-targeted immunosensor was reported as easy-to-use device for rapid quantication of melatonin reaching micromolar LOD, which can be further potentially used as a POC device in the future. 132 Other sensing techniques were also successfully employed in developing electrochemical biosensor of AD with animal-sample tests, which include microelectrode array (MEA), 140 ratiometric photoacoustic nanoprobe, 141 and electrochemiluminescence. 142 As widely understood, tau protein is also an excellent candidate for human sample-based biosensor for AD. An electrochemical biosensor was recently developed to detect tau-381 based on aptamer-antibody sandwich assay in human serum from patients with AD. 143 DPV technique was used herein as quantication method resulting in LOD of 0.42 pM with 0.5 pM to 100 pM dynamic range. This biosensor combines the advantages of prominent affinity of aptamer with the signal amplication of the Au NPs yielding ultrasensitive detection means for tau protein in real human serum. Meanwhile, an electrochemical sensor based on a single bioreceptor, aptamer, immobilized in carboxyl graphene nanomaterials, thionin, and Au NPs modied glassy-carbon electrode was subsequently introduced. 144 However, the LOD in this work was found to be slightly higher (0.70 pM) than their previous report (0.42 pM). Nevertheless, both reports emphasize the capability of electrochemical based sensors as an early screening of AD, particularly for clinically relevant sample (i.e., real blood from AD patients). Further, it is noted that other biomarkers were also useful in human sample-based biosensor, such as ApoE4 gene from four genomic DNA samples extracted from human blood. 145 Despite technologically convenience and advantage offered by electrochemical method, the biomarker detection using this technique still exists several limitations and challenges that need to be overcome. For instance, the as-designed device usually lacks selectivity since the reference electrode limits the charge carriers, 146,147 sensor instability over prolonged storage time, limited design for multianalytes detection, and lack of regenerative sensor devices. 148 The further development should aim at addressing these issues and simultaneously maintain the forefront characteristics of electrochemical biosensors such as high sensitivity, device miniaturization capability, and relatively cost-effective in mass production.

(b) Fluorescent-based biosensors. Fluorescent-based techniques are highly sensitive, efficient, and specic for biomolecules detection. 149, 150 Conventional optical uorescence, however, exhibits several limitations as a POC diagnostic strategy due to the lack of portability, high cost, requirement of a specic prociency from the expert, and unsuitability in ambulatory environment. 150 To addresses these issues, a great effort has been made to develop a compact, portable, multiplexed, and cost-effective uorescent modalities 151-156 such as smartphone embedment, 157 uorescent lateral ow assay 158 etc.

As for the uorescent-based AD biosensors, series of biomarkers have been employed as an in vitro setting such as amyloid, 159-161 dopamine, 162-170 neurotoxin, 171 tau, 172 and ApoE4 DNA. 173 The major targeted analyte in this type of biosensor is AbO considered as the main culprit for AD initiation and progression. By quantifying AbO in CSF and plasma, it is found to be benecial for determining the disease severity. 174 Similar target was also detected by a quench body technique (denoted as Q-body) embedded to a uorescent sensor in an in vitro environment. 160 Q-body is a new kind of strategy to detect a broad range of biomolecules employing uorescence quenching of the dye(s) attached to the antibody fragment. 176 Previously, Ab-derived diffusible ligand (ADDL) was sensed by the double-labelled Fab type Q-bodies (the heavy and light chains) with a higher sensitivity than the Ab peptides suggesting the promising usage of Fab type Q-bodies as a notorious bioimaging tool. 160 It should be noted that uorescent-based technique also possesses several drawbacks, particularly in detecting the biomarkers of AD. On the one hand, label-based uorescent biosensing measurement is oen time consuming, cost-intensive, and possibly blockade the active binding sites in recognizing the targeted analytes. On the other hand, uorescent-based technique would potentially affect the affinity-based interaction of bioreceptor and the biomarkers. 177 Nonetheless, this method has been widely used as "gold standard" in clinical setting particularly for monitoring of early stage of Ab nucleation owing to its robust staining properties and method's conveniences. 178, 179 In terms of clinical perspectives, uorescent technique has also been reported as procient transducers to sense AD biomarkers in human samples. 180 Rajasekhar et al. reported a near-infrared (NIR) uorescent-based biosensor constructed to detect amyloid aggregates in human brain tissue sample. 181 The authors used coumarin-quinoline (CQ) conjugate as the uorescent probe exhibiting $100-fold uorescence power in vitro once bound to Ab aggregates with augmented quantum yield. CQ showed non-toxic properties for neuronal cells and excellent permeability against BBB. CQ probe also demonstrated unequivocal selectivity towards the target protein as compared to other toxic protein aggregates such as tau, a-synuclein, and islet amyloid polypeptide in human brain tissue. This was currently regarded as a reliable method in distinguishing AD from tau pathology and mixed dementia. Uniquely, this study also reported in silico approach i.e., density functional theory (DFT), molecular docking, and molecular dynamics, to elucidate the binding characteristics of ThT (control) and CQ within Ab (42) bril and further dene the binding constant as compared to experimental data. Molecular structure of CQ and selective staining of Ab plaques in human brain tissue are represented by Fig. 5(A) while the staining on the same plaque without NFTs of tau and the neuritic component (stained only with Tau phos Ser396/Ser404 (PHF1) antibody) are depicted by part (B) and (C), respectively. Nevertheless, the overlaid image indicated there was no colocalization of PHF1 and CQ compound (Fig. 4(D) ). In this study, in silico study is benecial to elucidate the lowest energy conguration of ligand (ThT or CQ) and protein (Ab (42)) binding ( Fig. 5(E) ), to characterize the chemical bonding status, which is responsible for a binding motif (ligand-protein) and regarded as a validation of the experimental nding. [181] [182] [183] Zhao et al. also reported a uorescent-based aptasensor to detect amyloid markers by an employment of double stranded DNA (dsDNA)/GO as the uorescent probe yielding LOD down to 0.1 nM with a linear detectable range from 0.1 nM to 40 nM. 184 This technique could discriminate the sample from AD patients and healthy persons indicating its acceptable selectivity. Moreover, it is noted that GO has effectively participated in reducing the non-specic adsorption due to its large surface area which provide the enormous covalent conjugation with Ab (40) oligomers-targeting aptamer and therefore, improved the sensitivity and specicity of the device. 184 The role of nanomaterials in recent biosensor architecture is crucial to provide a high-performance sensing device in which for now and in the future, these will likely become a promising platform in disease screening as well as POC diagnosis of AD. Additionally, some recent studies also provide detailed explanation and strategies of uorescent-based based biosensor for AD under in vitro environment, [185] [186] [187] [188] due to their sensitivity and generally non-invasive.

(c) Plasmonic-assisted biosensors. Plasmonic-assisted sensor is one of the profound transducing methods of AD marker detection. For the plasmonic-assisted sensors, several biomarkers have been recently detected in vitro in correlation with AD viz. Ab, ApoE4 gene, vitamin B12, and tau proteins. 189 Capability of quantifying biomarker panel (more than one marker) is apparently one of the key futures of the successful diagnosis of AD. Since the recent data emphasize that AD is associated with multi-factorial markers, obtained from "omics" studies, particularly on its pathophysiological steps. 190, 191 A shape-code biosensor, an Au NPs-shape dependent embedded in distinct Localized Surface Plasmon Resonance (LSPR) was fabricated to detect multi-analyte of AD's biomarkers in articial blood sample. 21 The LSPR is dened as an optical phenomenon resulted from light when it contacts with conductive NPs with a smaller size than the incident light wavelength. The Au NPs and antibody were governed as recognition elements resulting in LOD of 34.9 fM, 26 fM, 23.6 fM for Ab (40) , Ab (42) , and tau protein, respectively, along with a broad linear working range from 1 Â 10 1 to 1 Â 10 8 fM. This designated biosensor was denoted as the rst shape-code biosensor for the detection of AD biomarkers. Likewise, another recent study demonstrated the hybrid mode of both plasmonic and photonic sensors capabilities. 192 An obvious light-matter interaction is allowed by this multiple biomarkers-based biosensor. This dual-transducing strategy emphasizes the ability of plasmonic method in the detection of multiple analytes in diagnosing AD. Moreover, several biomarkers were also detected by plasmonic method, particularly by size-, composition-, and shape-dependent LSPR. 193 The tremendously intense and localized electromagnetic elds induced by LSPR create an exhibited change in extinction and scattering spectra shis resulting in highly sensitive transducers of NPs in the local refractive index.

A biosensing platform based on LSPR on 2D-photonic crystal (2D-PC) and Au-coated 2D-PC was constructed to detect ADlinked DNA oligonucleotide associated with ApoE4 gene sequence in vitro. 194 ApoE gene is known as a gene which responsible for Alzheimer's progression. 195 The use of this modied LSPR in this study was able to enhance specicity of ApoE gene detection resulting in a promising proof-of-concept for the miniaturized and wearable biosensors in numerous diagnostic and defence applications. 194 An interesting part of LSPR is the capability to detect analyte down to single nanoparticle as well as probing tremendously small volumes down to very low LOD achievement and cost-effective device in sensing avenue. However, despite the tremendous merits of LSPR assay in biosensing elds, their practical and clinical applications are still limited. 196 This may gain further concerns, specically when this transducing method is being translated towards clinical diagnosis.

(d) Photoelectrochemical biosensors.

Photoelectrochemical (PEC) method is another alternative for the taubased biosensing owing to its femtomolar detection limit capability. 127 In PEC analysis, excited charge carriers are generated by a photoelectrode via harnessing light energy in which the photogenerated charges would be transported to the counter electrode through the external circuit. The minority carriers subsequently initiate redox reactions with sacricial scavengers at the semiconductor or electrolyte. 197 A PECbiosensor was developed to detect tau proteins using bismuth vanadate (BiVO 4 ) as an articial electron donor-free. 127 The sensor was fabricated by integrating molybdenum (Mo) dopant and iron oxyhydroxide (FeOOH) ad-layer into the BiVO 4 photoelectrode and using horseradish peroxidase (HRP)-triggered oxidation of 3,3 0 -diaminobenzidine (DAB) as signal amplier ( Fig. 6(A) ). Regardless of the absence in additional electron supplies, the FeOOH/Mo:BiVO 4 associated with the Tau5 antibody was able to generate strong current signals at 0 V under the white light-illuminated diode. The LOD and limit of quantitation (LOQ) of this approach were found at 1.59 fM and 4.11 fM, respectively. Accordingly, the LOD was compared with other values from electrochemical methods reported in literature ( Fig. 6(B) ) and tend to be the lowest among the designated studies.

(e) Field-effect transistor biosensors. Among various techniques used to detect the neurodegenerative biomarkers, a special interest is given towards FET-based sensors owing to their ultrasensitivity, wide ranging analytes detection, labelfree, selectivity, reusability, and real-time detection capability up to living cells monitoring. 198, 199 Silicon nanowire (SiNW)based FET is one of the most developed eld-effect devices, pioneered by Charles M. Lieber's group in 2001, 200, 201 particularly for biological detection. Several in vitro biosensing measurements were demonstrated for the detection of Ab (40) and metal ions associated with AD biomarkers. SiNWs-FET device was reported to be a functional device for amyloid detection with the use of aptamer as recognition element. 202 The binding mode of Ab aptamer-Ab showed in the range of 0.1 pg mL À1 to 10 mg mL À1 with the ultra-low detection limit (i.e., $20 fM) due to the single-trap phenomena revealed by the novel SiNWs-FET structures. SiNWs-FET was also able to detect and quantify extracellular Zn 2+ associated with neurotransmission and Ab brillation by using Zn 2+ -sensitive uorophore, FluoZin-3, in a real time in vitro environment (i.e., cultured cortical neurons). 203 This strategy can serve as a highly sensitive device via examining how Zn 2+ homeostasis modulates neuronal activities. Furthermore, it can be a useful strategy in neurodegenerative disease prevention.

In addition to the great attempts made by using 1D nanomaterials in diagnosis platform for AD, two dimensional (2D) nanomaterials serve as highly promising materials for FET biosensors owing to their fruitful structural and electronic properties, 199, 204 such as large surface-to-volume ratio, high electrical conductivity, fast electron transfer kinetic reaction, and easy functionalization. 205 For instance, a graphene-based FET (G-FET) was fabricated to monitor the Ab aggregation on the basis of ganglioside G M1 -enriched supported lipid bilayer (G M1 *-SLB/G-FET) (Fig. 7(A) ). 206 The as-fabricated G-FET device is capable of detecting and monitoring the early nucleation phase of amyloid formation. It shows a larger potential as a promising biomimetic sensor to investigate membranerelated protein functions and interaction kinetics, as compared to ThT assay. Indeed, concurrent detections of the Ab40 aggregation by both G M1 *-SLB/G-FET and ThT assays may benet in future diagnosis of AD (Fig. 7(B) ). 206 However, the ability of device to monitor the amyloid in the real sample (CSF or plasma) remains challenging with the presence of other interference proteins. Another vast obstacle of FET in clinical biosensing measurement relies on the high concentration of salts/buffers in clinical sample-induced Debye-Hückel screening effect. 79 Debye-Hückel effect is the discussion about the correlation of Debye length and unambiguous selective detection of macromolecules. Debye length (l D ) corresponds to the distance measured from FET-biosensor surface and electrolytic buffer solution (e.g., phosphate-buffered saline) describing the screening of surface charges by ions in an electrolyte solution. Debye length is described as the eqn (1) below, 

where the 3 0 represents the vacuum permittivity, 3 r is the relative permittivity of the medium, k B is the constant of Boltzmann (1.380649 Â 10 À23 J K À1 ), T is the absolute temperature (298 K), N A is the Avogadro's number (6.02214076 Â 10 23 mol À1 ), e is the elementary charge, and I represents the ionic strength. Ionic strength (I) is further given as follow (eqn (2)),

where C i represents the molar concentration (mol L À1 ) of the ion i, Z i is the charge number or valence of ion and the sum is taken over all the ions in the buffer solution. Another equation which also can be used to calculate the l D is given by,

where l B is the Bjerrum length (0.7 nm), S i is the sum of all ions, and r i and Z i are the density and valence, respectively, of ion species i. 207 A more simple equation can be used as described below (eqn (4)),

From these equations, the most important parameter is ionic strength (I) which directly determine the l D . The selection of biorecognition element is also crucial for FET biosensor, particularly for the needs to be applied to relatively high-salt biological samples, such as blood, CSF, sweat, etc. This effect may lead to the clearance of electrical signal produced by target-receptor binding affinity. 198 Also, it is suggested that the dimensional size of recognition elements need to be below l D in order to omit the Debye-Hückel screening effect. Instead, another general approach is by diluting the sample into several orders of concentration to increase l D .

Towards next-stage of pre-clinical based-in vitro biosensors, the use of animal biouid is the crucial steps of biosensor translational efforts, particularly for AD. As the frequent usage in electrochemical transducer, a recent immunosensing approach was developed to detect Ab (40) fragment in brain tissue lysates prepared from AD-induced rats. 133 The devoted impedimetric micro-immunosensing assay used monoclonal Ab (40) antibodies which were immobilized on a disc-shaped microelectrode surface connected to an impedimetric signal transducer resulting in 4.81 pg mL À1 ($1.11 pM) LOD with a dynamic range of 1-10 4 pg mL À1 ($0.23-24.02 pM). The constructed platform yielded a lower LOD as compared with the designated conventional ELISA method. On the other hand, the amyloid protein together with Cu 2+ ions were capable of being detected in plasma and hippocampus of rats with normal and AD by a single ratiometric platform with biological processes association and direct involvement of Cu 2+ ions in Ab (42) aggregation. 208 This dual detection mode was achieved by detection of Cu 2+ ions through neurokinin B and the Cu 2+ releasing from a complex while the ions tend to bind the Ab (42) protein in the solution. The detection limit was observed as low as 0.04 mM for Cu 2+ and 0.5 ng mL À1 ($1.108 mM) for Ab (42) .

In vitro measurement could also be carried out by using various transducing methods, such as interferometric reectance spectroscopy, 209 organic electrochemical transistor, 210 surface-enhanced Raman spectroscopy, 211, 212 and quantitative polymerase chain reaction. 213 These transducers can provide clinically relevant-LOD concentration, simplicity, and reasonable cost of production to an extent by depending on the targets in analyte-bioreceptor interaction type and their native environment. However, further studies are still required to conrm the selectivity and specicity of the device towards real clinical samples.

In vivo biosensors have been treated as one of the future technologies of personalized healthcare. An implantable biosensor in human body can deliver essential healthcare information of the patients by continuous monitoring basis which are benecial for reducing prolonged clinical procedures. This type of sensing platform is particularly important for those who need continuous healthcare monitoring. A small uctuation will be easily captured and further provide the "health status" of one which further designate the following necessary treatment or therapy. For the life-threatening disease such as cancers, cardiovascular, and nondegenerative disease, the in vivo biosensor may serve as "baseline"-associated device for the prevention of further serious problems or complex outcomes. Another scenario is to continuously monitor chemotherapeutic medicine which can yield the guesswork out of dosing by displaying an individualized report on the pharmacokinetics. Despite many reports in in vivo biosensors towards this direction, only few reports addressed preclinical studies or further approved for human implantation. 116 

The use of electrochemistry to measure electroactive neurotransmitters such as dopamine, serotonin, norepinephrine, and their metabolites, [163] [164] [165] [166] [167] [168] [169] [170] in whole animals is pioneered by Ralph Adams and his colleagues during the early 1970s 214 in which the dysregulation of these species can lead to AD. [215] [216] [217] Since then, the eld has emerged as one of the important facets in microsensor 218 and real-time biological events monitoring, particularly for living tissue environment 167,219-221 and single-cell analysis. 164, 222, 223 Indeed, conventional electrochemical techniques, i.e., voltammetric, impedimetric, amperometry, and potentiometric, preserve a modest strategy towards Ab detection in vivo. 224, 225 Voltammetric method tends to be the most frequently used herein. The sensor merely measures current-potential relationship in which the potential represents as ngerprint-like electrochemical parameter for the determined species while the current is directly proportional to the species. The voltammetric family includes differential pulse voltammetry (DPV), cyclic voltammetry (CV), stripping voltammetry, AC voltammetry, linear sweep voltammetry (LSV), polarography, etc. Among in vitro and in vivo biosensing techniques, DPV seems to be favourable in measuring amyloid biomarkers, particularly for quantitative analysis. Whilst, CV has been widely employed for chemical modications due to its capability to quantify the redox behaviour of deposited nanomaterials in a triangular shape.

Microelectrode, a micro/nanoscale dimension of chemical sensors, has been widely developed as in vivo biosensing strategy to directly measure the analyte concentration inside the brain based on potential changes across chemically selective membranes at their tip. 167 Ding et al. developed an Aumicroelectrode biosensor to detect Ab level from CSF of live mice in situ. 225 They governed hemin and Cu 2+ ion that typically bind to Ab to induce strong coordination of Cu 2+ , Ab, and hemin. The deposited silver NPs onto Au-microelectrode respond to dynamic alterations of the Ab, which is subsequently turned into an amplied selective signal. The CSF was sampled from cisterna magna of the mice vigilantly using microneedle to avoid the blood vessels damage. EIS and LSV methods were employed to characterize the probes-deposition and to quantify Ab level, respectively. The detection limit was shown at 0.2 pM along with wide linear range from 1 pM to 50 nM. Similar concept of electrochemical application was extended using silk broin material by Liu et al. on the development of POC device for Ab detection based on blood sample. 226 In addition, a thorough discussion on state-of-the-art of microelectrode-based in vivo neurochemicals sensing has been discussed in a review by Xu et al. 227 A microelectrode principle was further employed by Peng et al. using carbon bre to monitor the superoxide anion radical (O 2 c À ) which directly correlate with production of reactive oxygen species-induced Ab. 224 They engineered ionic-liquid polymer with carbon nanotubes to mask the immobilized oxide dismutase (i.e., catalysing O 2 c À into peroxide species) from the enzyme leakage thereby, achieving better sensitivity (Fig. 8) . In vivo experiment was carried out by implanting the microelectrode into live rats' corpus striatum. The catalytic processes were examined using CV and amperometric methods. This study was able to exhibit as low as 0.42 mM of LOD with a decent linear relationship towards O 2 c À from 1.0 to 228.0 mM. The results also manifested the use of functionalized ionic liquid polymer (PIL) to preserve electrocatalytic activity, augment the stability, and serve as potential low-toxic matrix to support the substrate binding (e.g., enzyme or probe).

For the in vivo biosensor, the need for miniaturized working electrode is important to minimize the possible adverse effect of tissue damage during implantation and to increase the spatial resolution towards probe discrete brain regions as well as the sampling rates. 218 Furthermore, translating the in vivo application into real human application remains another critical challenge. There are various biological aspects to be considered, which may differ in expected outcomes with the in vivo, such as uncontrolled inorganic material degradation of the implant in a complex biouid. Other assessments are required, including systemic toxicity, immune response, irritation, that have satisfactorily been discussed by Gray and coworkers. 115 

Current development of biosensors has been paving the way on translating the sensing functionality to the personal healthcare device. Several types of biosensor products have successfully been distributed globally, including the blood-glucose, uric acid, cholesterol, and tropical disease diagnostics, which further improve the health core-facility down to suburban settings or the remote endemic. More importantly, the integrated application to non-invasively monitor the disease could facilitate better progress and plans for future medication. The presence of this particular technology should possibly never shirk the low cost and uncomplicated processing of a device. In accordance with this, the instrument-less biosensor, like a paper-based diagnostic tool, seems to be promising commercialization thereof. 228, 229 Concurrently, there is a new trend in wearable sensors which have been reaching the public market since 2014 and expected to substantially increase by the year of progress. 229 Compared to the POC, this type of marketable sensor is predicted to supplement the market along with the highly needs for the updated smart device. However, several obstacles related to their capability prior to public commercialization need to be addressed. The instability of the device is the bottleneck that seems perpetual. The device must cope with the dynamic biouid, entangled constituents present in the biouid, and biorecognition capability during the period of use. [230] [231] [232] [233] The robust transmission of the generated signal to translate the detection into readable or report-mode is also considered. The ideal wearable sensor may not be seen as yet, but the promising concept has been one-by-one adequately delivered and fenced with full delicacy to improve the personalized healthcare in the future. 

Designing suitable and reliable biosensor for AD have continually attracted great interests with the noteworthy growth in recent years. The key factors of these biosensor designs are based on the progress by corresponding biomarkers, sample sources, nanomaterials used as well as advanced transducing techniques. Particularly, it is worth to note that electrochemical biosensor is the most common technique to produce biosensor along with Ab peptide and tau protein as frequent targets for diagnosing AD. The excellent sensitivity, easy-to-use, simple fabrication, and good selectivity which could be reached through this device architecture. Instead, the closeness and convenience to the end-users are other remarkable benets of the electrochemical sensing inspired from the success story of glucose monitoring devices which are widely available as POC testing in market. On the other hand, plasmonic detection and uorescent biosensor are also taken into account as promising strategies for diagnosing AD. Numerous types of other biosensors may serve as alternative methods towards POC diagnostics of the AD. Moreover, theoretical chemistry has admittedly validated and supported the experimental results by its central contributions towards determining the optimized geometry and binding motif of attributed molecular interactions (i.e., via molecular dynamics and molecular docking).

Non-invasiveness of the sampling method and device sensitivity are the critical points in the successful development of biosensor for AD. Complying the POC diagnostics, further research could be conducted towards development of ultraperformance biosensors architecture by using biocompatible nanomaterials (e.g., polyethylene glycol, chitosan, biopolymer, etc.), minimally-invasive samples (e.g., blood, saliva), and attempting to reach single molecule analyte as ultimate goal of the device construction. However, from the physician viewpoint, the urgent need in current diagnostic device is not only devoted on the ultrasensitivity feature, but also the wide dynamic or linear range covering the clinical concentration of AD biomarkers. Molecular electronics and self-powered biosensors appear to be the future of bioelectronics. Currently, miniaturization of the system entering the mobile world (i.e., biosensors based on mobile phone; Android or IOS) and self-powered device are vastly considerable in revealing advanced, smart, and early POC-and even beyond, eHealth-, based diagnosis platform of the disease. 

There are no conicts to declare.

Alzheimer's Dement

Kovacs and I. Alafuzoff

Compendium of chemical terminology (the "Gold Book

Alzheimer's Dement

Nanomaterials for Biosensors

Ensuring innovation in diagnostics for bacterial infection: implications for policy, World Health Organization

Nanotechnology and Microuidics

Document search

Advanced Biosensors for Health Care Applications

Alzheimer's Dis

Alzheimer's Res

Label-free biosensing: advanced materials, devices and applications

Monolayers of Emerging Nanomaterials, IntechOpen

Published by the